KCNQ2 encephalopathy is a rare developmental and epileptic encephalopathy (DEE) caused by heterozygous variants in the KCNQ2 gene (potassium channel KQT-like subfamily member 2). The disorder typically presents within the first week of life with tonic (spasm-like) seizures, often progressing to multiple seizure types. The seizure burden is often severe in infancy but frequently improves substantially over the first 1–2 years, distinguishing it from some other DEEs. However, most patients retain significant developmental impairment, motor dysfunction, and cognitive disability despite seizure improvement.
Prevalence estimates suggest KCNQ2 encephalopathy accounts for ~5-10% of neonatal-onset epilepsies, with an estimated incidence of 1:50,000–100,000 live births. The majority of cases are de novo, though familial cases with incomplete penetrance have been reported@kcnq2review2022.
KCNQ2 is located on chromosome 20q13.33 and encodes the Kv7.2 subunit of the voltage-gated potassium channel M-current. The M-current is a critical regulator of neuronal excitability: it stabilizes the resting membrane potential and prevents excessive firing. The channel is a tetramer of four Kv7.2 (KCNQ2) or Kv7.3 (KCNQ3) subunits, with KCNQ2:KCNQ3 heterotetramers being the predominant composition in forebrain neurons.
Pathogenic variants in KCNQ2 produce loss-of-function through several mechanisms:
The majority of pathogenic variants are missense, but nonsense and frameshift variants are also observed. Notably, gain-of-function variants in KCNQ2 cause a distinct disorder (benign familial neonatal seizures, BFNS), while loss-of-function causes KCNQ2 encephalopathy@kcnq2review2022.
Loss of M-current function leads to hyperexcitability through:
The paradox of severe neonatal seizures with later improvement may reflect developmental upregulation of KCNQ3 and other compensation mechanisms.
The hallmark is seizure onset within the first week, often within hours of birth. Seizures are typically tonic (stiffening) or focal clonic, often prolonged (status epilepticus in >50%). Multiple seizures per day are common. Importantly, many patients have continuous or near-continuous epileptiform EEG activity (burst suppression or electrical status epilepticus).
Multiple seizure types may emerge:
Developmental plateau or regression begins in this period.
Seizure trajectory: A distinguishing feature of KCNQ2 encephalopathy is that many patients experience significant seizure improvement by 1-3 years of age. However, this improvement is not universal, and some patients continue to have seizures.
Developmental trajectory: Regardless of seizure outcome, most patients have significant neurodevelopmental impairment:
Genetic counseling is important because some parents carry the variant in mosaic form, affecting recurrence risk.
| Drug | Evidence | Notes |
|---|---|---|
| Sodium channel blockers (phenytoin, carbamazepine) | Moderate | May be effective; paradoxically, these work in KCNQ2 where other channelopathies worsen |
| Levetiracetam | Low-moderate | Commonly used but limited efficacy |
| Valproic acid | Low-moderate | First-line in some centers |
| Benzodiazepines (clobazam, clonazepam) | Low | Useful for acute seizure clusters |
| Vigabatrin | Low | May help infantile spasms component |
| Corticosteroids (prednisone, ACTH) | Low | For infantile spasms; mixed response |
Ezogabine (potassium channel opener, FDA-approved for focal seizures) has been explored in KCNQ2 encephalopathy given its mechanism of action, but data are limited and cardiac monitoring (QT prolongation) is required.
KCNQ2 encephalopathy is an attractive target for gene therapy because:
| Program | Developer | Approach | Stage |
|---|---|---|---|
| AAV-KCNQ2 | Academic (multiple groups) | Gene replacement | Preclinical |
| KCNQ2 ASO | Various | Increase expression | Preclinical |
See clinical trial page for KCNQ2 encephalopathy for details on the current landscape.
| Outcome | Details |
|---|---|
| Seizure outcome | ~60-70% achieve seizure freedom or significant reduction by age 2-3 |
| Cognitive outcome | ~90% have ID; severity ranges from moderate to profound |
| Motor | Hypotonia early, may develop spasticity; ataxia common |
| Behavioral | Autism features in 40-60%; ADHD, anxiety frequent |
| Mortality | Lower than Dravet syndrome; SUDEP remains a risk |